Body mass index associates with amyotrophic lateral sclerosis survival and metabolomic profiles
dc.contributor.author | Goutman, Stephen A. | |
dc.contributor.author | Boss, Jonathan | |
dc.contributor.author | Iyer, Gayatri | |
dc.contributor.author | Habra, Hani | |
dc.contributor.author | Savelieff, Masha G. | |
dc.contributor.author | Karnovsky, Alla | |
dc.contributor.author | Mukherjee, Bhramar | |
dc.contributor.author | Feldman, Eva L. | |
dc.date.accessioned | 2023-03-03T21:10:02Z | |
dc.date.available | 2024-04-03 16:10:01 | en |
dc.date.available | 2023-03-03T21:10:02Z | |
dc.date.issued | 2023-03 | |
dc.identifier.citation | Goutman, Stephen A.; Boss, Jonathan; Iyer, Gayatri; Habra, Hani; Savelieff, Masha G.; Karnovsky, Alla; Mukherjee, Bhramar; Feldman, Eva L. (2023). "Body mass index associates with amyotrophic lateral sclerosis survival and metabolomic profiles." Muscle & Nerve 67(3): 208-216. | |
dc.identifier.issn | 0148-639X | |
dc.identifier.issn | 1097-4598 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/175919 | |
dc.description.abstract | Introduction/AimsBody mass index (BMI) is linked to amyotrophic lateral sclerosis (ALS) risk and prognosis, but additional research is needed. The aim of this study was to identify whether and when historical changes in BMI occurred in ALS participants, how these longer term trajectories associated with survival, and whether metabolomic profiles provided insight into potential mechanisms.MethodsALS and control participants self-reported body height and weight 10 (reference) and 5 years earlier, and at study entry (diagnosis for ALS participants). Generalized estimating equations evaluated differences in BMI trajectories between cases and controls. ALS survival was evaluated by BMI trajectory group using accelerated failure time models. BMI trajectories and survival associations were explored using published metabolomic profiling and correlation networks.ResultsTen-year BMI trends differed between ALS and controls, with BMI loss in the 5 years before diagnosis despite BMI gains 10 to 5 years beforehand in both groups. An overall 10-year drop in BMI associated with a 27.1% decrease in ALS survival (P = .010). Metabolomic networks in ALS participants showed dysregulation in sphingomyelin, bile acid, and plasmalogen subpathways.DiscussionALS participants lost weight in the 5-year period before enrollment. BMI trajectories had three distinct groups and the group with significant weight loss in the past 10 years had the worst survival. Participants with a high BMI and increase in weight in the 10 years before symptom onset also had shorter survival. Certain metabolomics profiles were associated with the BMI trajectories. Replicating these findings in prospective cohorts is warranted.See Editorial on pages 191-192 in this issue | |
dc.publisher | John Wiley & Sons, Inc. | |
dc.subject.other | amyotrophic lateral sclerosis | |
dc.subject.other | metabolism | |
dc.subject.other | prognosis | |
dc.subject.other | survival | |
dc.subject.other | body mass index | |
dc.title | Body mass index associates with amyotrophic lateral sclerosis survival and metabolomic profiles | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Neurosciences | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175919/1/mus27744.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175919/2/mus27744_am.pdf | |
dc.identifier.doi | 10.1002/mus.27744 | |
dc.identifier.source | Muscle & Nerve | |
dc.identifier.citedreference | Lawton KA, Brown MV, Alexander D, et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15 ( 5–6 ): 362 - 370. doi: 10.3109/21678421.2014.908311 | |
dc.identifier.citedreference | Ma J, Karnovsky A, Afshinnia F, et al. Differential network enrichment analysis reveals novel lipid pathways in chronic kidney disease. Bioinformatics. 2019; 35 ( 18 ): 3441 - 3452. doi: 10.1093/bioinformatics/btz114 | |
dc.identifier.citedreference | Lancichinetti A, Fortunato S. Consensus clustering in complex networks. Sci Rep. 2012; 2 ( 1 ): 336. doi: 10.1038/srep00336 | |
dc.identifier.citedreference | Friedman J, Hastie T, Tibshirani R. A note on the group lasso and a sparse group lasso. arXiv. 2010; 22: 10010736. | |
dc.identifier.citedreference | Huisman MH, Seelen M, van Doormaal PT, et al. Effect of presymptomatic body mass index and consumption of fat and alcohol on amyotrophic lateral sclerosis. JAMA Neurol. 2015; 72 ( 10 ): 1155 - 1162. doi: 10.1001/jamaneurol.2015.1584 | |
dc.identifier.citedreference | Westeneng HJ, van Veenhuijzen K, van der Spek RA, et al. Associations between lifestyle and amyotrophic lateral sclerosis stratified by C9orf72 genotype: a longitudinal, population-based, case-control study. Lancet Neurol. 2021; 20 ( 5 ): 373 - 384. doi: 10.1016/S1474-4422(21)00042-9 | |
dc.identifier.citedreference | Janse van Mantgem MR, van Eijk RPA, van der Burgh HK, et al. Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2020; 91 ( 8 ): 867 - 875. doi: 10.1136/jnnp-2020-322909 | |
dc.identifier.citedreference | Nakamura R, Kurihara M, Ogawa N, et al. Prognostic prediction by hypermetabolism varies depending on the nutritional status in early amyotrophic lateral sclerosis. Sci Rep. 2021; 11 ( 1 ): 17943. doi: 10.1038/s41598-021-97196-5 | |
dc.identifier.citedreference | Jésus P, Fayemendy P, Nicol M, et al. Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2018; 25 ( 1 ): 97 - 104. doi: 10.1111/ene.13468 | |
dc.identifier.citedreference | Bjornevik K, Zhang Z, O’Reilly ÉJ, et al. Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology. 2019; 92 ( 18 ): e2089 - e2100. doi: 10.1212/wnl.0000000000007401 | |
dc.identifier.citedreference | Lawton KA, Cudkowicz ME, Brown MV, et al. Biochemical alterations associated with ALS. Amyotroph Lateral Scler. 2012; 13 ( 1 ): 110 - 118. doi: 10.3109/17482968.2011.619197 | |
dc.identifier.citedreference | Sol J, Jové M, Povedano M, et al. Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression. Brain Commun. 2021; 3 ( 3 ): fcab143. doi: 10.1093/braincomms/fcab143 | |
dc.identifier.citedreference | Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 2002; 52 ( 4 ): 448 - 457. doi: 10.1002/ana.10312 | |
dc.identifier.citedreference | Wang G, Bieberich E. Sphingolipids in neurodegeneration (with focus on ceramide and S1P). Adv Biol Regul. 2018; 70: 51 - 64. doi: 10.1016/j.jbior.2018.09.013 | |
dc.identifier.citedreference | Mohassel P, Donkervoort S, Lone MA, et al. Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nat Med. 2021; 27 ( 7 ): 1197 - 1204. doi: 10.1038/s41591-021-01346-1 | |
dc.identifier.citedreference | Di Ciaula A, Garruti G, Lunardi Baccetto R, et al. Bile acid physiology. Ann Hepatol. 2017; 16 ( Suppl. 1: s3–105 ): s4 - s14. doi: 10.5604/01.3001.0010.5493 | |
dc.identifier.citedreference | Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium Phenylbutyrate-Taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020; 383 ( 10 ): 919 - 930. doi: 10.1056/NEJMoa1916945 | |
dc.identifier.citedreference | Paganoni S, Hendrix S, Dickson SP, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021; 63 ( 1 ): 31 - 39. doi: 10.1002/mus.27091 | |
dc.identifier.citedreference | Parry GJ, Rodrigues CM, Aranha MM, et al. Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic acid in patients with amyotrophic lateral sclerosis. Clin Neuropharmacol. 2010; 33 ( 1 ): 17 - 21. doi: 10.1097/WNF.0b013e3181c47569 | |
dc.identifier.citedreference | Min JH, Hong YH, Sung JJ, Kim SM, Lee JB, Lee KW. Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial. J Korean Med Sci. 2012; 27 ( 2 ): 200 - 206. doi: 10.3346/jkms.2012.27.2.200 | |
dc.identifier.citedreference | Blasco H, Veyrat-Durebex C, Bocca C, et al. Lipidomics reveals cerebrospinal-fluid signatures of ALS. Sci Rep. 2017; 7 ( 1 ): 17652. doi: 10.1038/s41598-017-17389-9 | |
dc.identifier.citedreference | Chang KH, Lin CN, Chen CM, et al. Altered metabolic profiles of the plasma of patients with amyotrophic lateral sclerosis. Biomedicine. 2021; 9 ( 12 ): 1944. doi: 10.3390/biomedicines9121944 | |
dc.identifier.citedreference | van Eunen K, Simons SM, Gerding A, et al. Biochemical competition makes fatty-acid β-oxidation vulnerable to substrate overload. PLoS Comput Biol. 2013; 9 ( 8 ): e1003186. doi: 10.1371/journal.pcbi.1003186 | |
dc.identifier.citedreference | Lee I, Kazamel M, McPherson T, et al. Fat mass loss correlates with faster disease progression in amyotrophic lateral sclerosis patients: exploring the utility of dual-energy x-ray absorptiometry in a prospective study. PLoS One. 2021; 16 ( 5 ): e0251087. doi: 10.1371/journal.pone.0251087 | |
dc.identifier.citedreference | Li C, Ou R, Wei Q, Shang H. Shared genetic links between amyotrophic lateral sclerosis and obesity-related traits: a genome-wide association study. Neurobiol Aging. 2021; 102: 211 e1 - 211 e9. doi: 10.1016/j.neurobiolaging.2021.01.023 | |
dc.identifier.citedreference | Zhang L, Tang L, Huang T, Fan D. Life course adiposity and amyotrophic lateral sclerosis: a Mendelian randomization study. Ann Neurol. 2020; 87 ( 3 ): 434 - 441. doi: 10.1002/ana.25671 | |
dc.identifier.citedreference | Fernihough A, McGovern ME. Physical stature decline and the health status of the elderly population in England. Econ Hum Biol. 2015; 16: 30 - 44. doi: 10.1016/j.ehb.2013.12.010 | |
dc.identifier.citedreference | Goutman SA, Hardiman O, Al-Chalabi A, et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol. 2022; 21 ( 5 ): 480 - 493. doi: 10.1016/S1474-4422(21)00465-8 | |
dc.identifier.citedreference | Goutman SA, Hardiman O, Al-Chalabi A, et al. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022; 21 ( 5 ): 465 - 479. doi: 10.1016/S1474-4422(21)00414-2 | |
dc.identifier.citedreference | Benatar M, Turner MR, Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019; 20 ( 5–6 ): 303 - 309. doi: 10.1080/21678421.2019.1587634 | |
dc.identifier.citedreference | Moglia C, Calvo A, Grassano M, et al. Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. J Neurol Neurosurg Psychiatry. 2019; 90 ( 6 ): 666 - 673. doi: 10.1136/jnnp-2018-319611 | |
dc.identifier.citedreference | Peter RS, Rosenbohm A, Dupuis L, et al. Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia. Eur J Epidemiol. 2017; 32 ( 10 ): 901 - 908. doi: 10.1007/s10654-017-0318-z | |
dc.identifier.citedreference | Nakken O, Meyer HE, Stigum H, Holmoy T. High BMI is associated with low ALS risk: a population-based study. Neurology. 2019; 93 ( 5 ): e424 - e432. doi: 10.1212/WNL.0000000000007861 | |
dc.identifier.citedreference | O’Reilly ÉJ, Wang H, Weisskopf MG, et al. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14 ( 3 ): 205 - 211. doi: 10.3109/21678421.2012.735240 | |
dc.identifier.citedreference | O’Reilly EJ, Wang M, Adami HO, et al. Prediagnostic body size and risk of amyotrophic lateral sclerosis death in 10 studies. Amyotroph Lateral Scler Frontotemporal Degener. 2018; 19 ( 5–6 ): 396 - 406. doi: 10.1080/21678421.2018.1452944 | |
dc.identifier.citedreference | Mariosa D, Beard JD, Umbach DM, et al. Body mass index and amyotrophic lateral sclerosis: a study of US military veterans. Am J Epidemiol. 2017; 185 ( 5 ): 362 - 371. doi: 10.1093/aje/kww140 | |
dc.identifier.citedreference | Gallo V, Wark PA, Jenab M, et al. Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort. Neurology. 2013; 80 ( 9 ): 829 - 838. doi: 10.1212/WNL.0b013e3182840689 | |
dc.identifier.citedreference | Ioannides ZA, Ngo ST, Henderson RD, McCombe PA, Steyn FJ. Altered metabolic homeostasis in amyotrophic lateral sclerosis: mechanisms of energy imbalance and contribution to disease progression. Neurodegener Dis. 2016; 16 ( 5–6 ): 382 - 397. doi: 10.1159/000446502 | |
dc.identifier.citedreference | Steyn FJ, Ioannides ZA, van Eijk RPA, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry. 2018; 89 ( 10 ): 1016 - 1023. doi: 10.1136/jnnp-2017-317887 | |
dc.identifier.citedreference | Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011; 10 ( 1 ): 75 - 82. doi: 10.1016/S1474-4422(10)70224-6 | |
dc.identifier.citedreference | Mariosa D, Hammar N, Malmstrom H, et al. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20-year follow-up of the Swedish AMORIS cohort. Ann Neurol. 2017; 81 ( 5 ): 718 - 728. doi: 10.1002/ana.24936 | |
dc.identifier.citedreference | Ingre C, Chen L, Zhan Y, Termorshuizen J, Yin L, Fang F. Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis. Neurology. 2020; 94 ( 17 ): e1835 - e1844. doi: 10.1212/WNL.0000000000009322 | |
dc.identifier.citedreference | Cirulli ET, Guo L, Leon Swisher C, et al. Profound perturbation of the metabolome in obesity is associated with health risk. Cell Metab. 2019; 29 ( 2 ): 488 - 500.e2. doi: 10.1016/j.cmet.2018.09.022 | |
dc.identifier.citedreference | Ho JE, Larson MG, Ghorbani A, et al. Metabolomic profiles of body mass index in the Framingham heart study reveal distinct cardiometabolic phenotypes. PLoS One. 2016; 11 ( 2 ): e0148361. doi: 10.1371/journal.pone.0148361 | |
dc.identifier.citedreference | Kraus WE, Pieper CF, Huffman KM, et al. Association of plasma small-molecule intermediate metabolites with age and body mass index across six diverse study populations. J Gerontol A Biol Sci Med Sci. 2016; 71 ( 11 ): 1507 - 1513. doi: 10.1093/gerona/glw031 | |
dc.identifier.citedreference | Goutman SA, Boss J, Patterson A, Mukherjee B, Batterman S, Feldman EL. High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019; 90 ( 8 ): 907 - 912. doi: 10.1136/jnnp-2018-319785 | |
dc.identifier.citedreference | Su FC, Goutman SA, Chernyak S, et al. Association of environmental toxins with amyotrophic lateral sclerosis. JAMA Neurol. 2016; 73 ( 7 ): 803 - 811. doi: 10.1001/jamaneurol.2016.0594 | |
dc.identifier.citedreference | Yu Y, Su FC, Callaghan BC, Goutman SA, Batterman SA, Feldman EL. Environmental risk factors and amyotrophic lateral sclerosis (ALS): a case-control study of ALS in Michigan. PloS One. 2014; 9 ( 6 ): e101186. doi: 10.1371/journal.pone.0101186 | |
dc.identifier.citedreference | Goutman SA, Boss J, Godwin C, Mukherjee B, Feldman EL, Batterman SA. Associations of self-reported occupational exposures and settings to ALS: a case-control study. Int Arch Occup Environ Health. 2022; 95 ( 7 ): 1567 - 1586. doi: 10.1007/s00420-022-01874-4 | |
dc.identifier.citedreference | Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000; 1 ( 5 ): 293 - 299. doi: 10.1080/146608200300079536 | |
dc.identifier.citedreference | Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. J Chronic Dis. 1972; 25 ( 6 ): 329 - 343. doi: 10.1016/0021-9681(72)90027-6 | |
dc.identifier.citedreference | Goutman SA, Boss J, Guo K, et al. Untargeted metabolomics yields insight into ALS disease mechanisms. J Neurol Neurosurg Psychiatry. 2020; 91 ( 12 ): 1329 - 1338. doi: 10.1136/jnnp-2020-323611 | |
dc.identifier.citedreference | Goutman SA, Guo K, Savelieff MG, et al. Metabolomics identifies shared lipid pathways in independent amyotrophic lateral sclerosis cohorts. Brain J Neurol. 2022; awac025. doi: 10.1093/brain/awac025 | |
dc.identifier.citedreference | Liang KY, Zeger SL. Longitudinal data-analysis using generalized linear-models. Biometrika. 1986; 73 ( 1 ): 13 - 22. doi: 10.1093/biomet/73.1.13 | |
dc.identifier.citedreference | Halekoh U, Højsgaard S, Yan J. The R package geepack for generalized estimating equations. J Stat Softw. 2006; 15 ( 2 ): 1 - 11. doi: 10.18637/jss.v015.i02 | |
dc.identifier.citedreference | Genolini C, Alacoque X, Sentenac M, Arnaud C. kml and kml3d: R packages to cluster longitudinal data. J Stat Softw. 2015; 65 ( 4 ): 34. doi: 10.18637/jss.v065.i04 | |
dc.identifier.citedreference | Calinski T, Harabasz J. A dendrite method for cluster analysis. Commun Stat Theory Methods. 1974; 3 ( 1 ): 1 - 27. doi: 10.1080/03610927408827101 | |
dc.identifier.citedreference | Gower JC. Some distance properties of latent root and vector methods used in multivariate analysis. Biometrika. 1966; 53 ( 3/4 ): 325. doi: 10.1093/biomet/53.3-4.325 | |
dc.identifier.citedreference | Basu S, Duren W, Evans CR, Burant CF, Michailidis G, Karnovsky A. Sparse network modeling and metscape-based visualization methods for the analysis of large-scale metabolomics data. Bioinformatics. 2017; 33 ( 10 ): 1545 - 1553. doi: 10.1093/bioinformatics/btx012 | |
dc.identifier.citedreference | Iyer GR, Wigginton J, Duren W, et al. Application of differential network enrichment analysis for deciphering metabolic alterations. Metabolites. 2020; 10 ( 12 ): 479. doi: 10.3390/metabo10120479 | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.